Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Wes Lindsey, PhD, MBA as its new Chief Scientific Officer, the Salt Lake City-based molecular diagnostics company announced.

Dr. Lindsey holds a PhD in Genetics and Molecular Biology from Emory University and an MBA from Georgia State University. He brings more than 20 years of experience in molecular diagnostics, including leading assay development and R&D teams that produced more than a dozen FDA 510(k) submissions and CE-marked assays for in vitro diagnostic products.

"Wes brings two decades of experience building and leading molecular diagnostics teams through FDA clearance, including point-of-care and near-point-of-care IVDs, and that expertise will play an important role in our regulatory submissions for the Co-Dx PCR platform and our continued pipeline expansion," said Dwight Egan, Chief Executive Officer of Co-Diagnostics.

The company's Co-Dx PCR platform, which includes the PCR Home and PCR Pro devices, a mobile app, and associated tests, is currently under FDA review and is not yet available for sale.